Special Invitation: PDF OnlyPotential therapeutic agents against COVID-19 What we know so farLu, Chih-Chiaa; Chen, Mei-Yua; Chang, Yuh-Liha,b,*Author Information aDepartment of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC b Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC Received date: March 29, 2020. Accepted date: March 29, 2020. Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article. Address Corresponcence. Dr. Yuh-Lih Chang, Department of Pharmacy, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, ROC. E-mail: firstname.lastname@example.org This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Journal of the Chinese Medical Association: April 1, 2020 - Volume Latest Articles - Issue - doi: 10.1097/JCMA.0000000000000318 Open PAP Metrics Abstract The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19. © 2020 by Lippincott Williams & Wilkins, Inc.